Federal grants to L2 Diagnostics LLC
L2 Diagnostics LLC in New Haven, Connecticut received $8.8 million in federal grants from fiscal 2021 to 2025, across 14 awards. Its largest program was Allergy and Infectious Diseases Research, with $8.5 million. In fiscal 2025 it was awarded $2.4 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$8.8 million
- Awards14
- Awarded in FY 2025$2.4 million
- Largest award$2.9 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $1.3 million |
| FY 2022 | 3 | $2.0 million |
| FY 2023 | 1 | $979,482 |
| FY 2024 | 6 | $2.2 million |
| FY 2025 | 9 | $2.4 million |
Programs that fund L2 Diagnostics LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 13 | $8.5 million |
| National Center for Advancing Translational Sciences | 1 | $299,878 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 14 | $8.8 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| A novel vaccine against mosquito-borne zika virus based on mosquito salivary gland protein AGBR1 - summary arboviruses present a constant threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, primarily mosquitoes. One of them, aedes aegypti, is the primary ve | Allergy and Infectious Diseases Research | August 18, 2022 | $2.9 million |
| An antigen-detection assay to diagnose babesia microti infection | Allergy and Infectious Diseases Research | May 10, 2021 | $1.4 million |
| The mosquito salivary protein AGBR1 as vaccine candidate against chikungunya - project summary chikungunya is an arboviral disease transmitted to humans by infected mosquitoes, primarily the aedes aegypti and aedes albopictus species. The virus responsible for the disease is the chikungunya virus (c | Allergy and Infectious Diseases Research | July 17, 2024 | $599,938 |
| A novel therapeutic for lyme arthritis based on a secretory leukocyte protease inhibitor - project summary/abstract lyme disease (LD), the most common tick-borne disease in the united states, is caused by a spirochete, borrelia burgdorferi. An estimated 500,000 people are diagnosed and treated each | Allergy and Infectious Diseases Research | July 8, 2024 | $599,866 |
| A therapeutic for lyme disease based on peptidoglycan recognition protein 1 - abstract lyme disease, the most common vector-borne illness in north america, is caused by the spirochete b. Burgdorferi. Infection begins in the skin following an infected tick-bite and acute illness is characterized by h | Allergy and Infectious Diseases Research | August 4, 2021 | $599,028 |
| A multivalent mrna vaccine to prevent transmission of tick-bornepathogens | Allergy and Infectious Diseases Research | April 29, 2024 | $597,612 |
| Pfag, a multivalent peptide vaccine against malaria - abstract pfag is our novel malaria vaccine, composed of short synthetic peptides representing specific immunogenic epitopes of the plasmodium falciparum circumsporozoite (CSP) and anopheles gambiae trio (ag trio) proteins. Our prototype pf ag has | Allergy and Infectious Diseases Research | September 15, 2025 | $299,954 |
| Delivery of a candidate agtriovx malaria vaccine by thermostable microneedle patches - abstract malaria remains one of the deadliest infectious diseases. Although much progress has been made in the fight against malaria, a highly effective and durable vaccine is not available. New vaccine candidates | National Center for Advancing Translational Sciences | September 5, 2024 | $299,878 |
| Delivery of a candidate agtriovx malaria vaccine by thermostable microneedle patches - abstract malaria remains one of the deadliest infectious diseases. Although much progress has been made in the fight against malaria, a highly effective and durable vaccine is not available. New vaccine candidates | Allergy and Infectious Diseases Research | May 28, 2024 | $299,862 |
| A vaccine targeting mosquito metabolic pathways to eradicate malaria - abstract the world health organization, NIH/niaid, and other public health organizations have recently highlighted the urgent need for a mosquito pathogen transmission-blocking vaccine (TBV) to be used alongside the recent rts,s, | Allergy and Infectious Diseases Research | September 23, 2025 | $299,644 |
Questions people ask
How much federal grant money does L2 Diagnostics LLC get?
$8.8 million in 14 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives L2 Diagnostics LLC the most?
The Department of Health and Human Services, with $8.8 million in 14 awards.
What is L2 Diagnostics LLC's largest federal grant?
$2.9 million under Allergy and Infectious Diseases Research, with its first action in the period on August 18, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund L2 Diagnostics LLC?
Its largest are Allergy and Infectious Diseases Research and National Center for Advancing Translational Sciences.
Other grant recipients in New Haven
- Yale Univ
- City of New Haven
- Housing Authority of the City of New Haven
- Cornell Scott Hill Health Corporation
- Southern Connecticut State University
- City of New Haven
- Fair Haven Community Health Clinic, Inc.
- Higher Education, Connecticut Board of Regents for
Largest federal grant recipients in Connecticut · Federal grants in Connecticut